ITOS - iTeos Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

160.3M

Cash

449.1M

Avg Qtr Burn

-27.4M

Short % of Float

10.52%

Insider Ownership

0.71%

Institutional Own.

99.78%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Belrestotug (EOS-448) + Dostarlimab (doublet) + Nelistotug (triplet) Details Cancer, Head and neck squamous cell carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Belrestotug (EOS-448) + Dostarlimab (doublet) Details Cancer, Non-small cell lung carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Inupadenant (EOS-850) Details Cancer, Non-small cell lung carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EOS-984 Details Solid tumor/s, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.